

UNITED STATES OF AMERICA Federal Trade Commission WASHINGTON, D.C. 20580

September 5, 2017

John R. Ingrassjæsq. Proskauer Rose LLP Counsel For Grifols, S.A. 1001 Pennsylvania Avneue, N.W. Suite 600 South Washington, DC 200022533

Re: In the Matter of Grifols, S.A., and Talecris Biotherapeutics Holdings Corp. Docket No. C4322

Dear Mr. Ingrassia:

Pursuant to Rule 2.41(f) of the commission Rules of Practice Commission has determined to approve the Application filed by Grifols, S.A., on June 12, 2017, to modify the Contract Manufacturing Agreement ("CMAII) corporated into the Decision and Order in this matter by approving the raft Amendment to the CMAIn according its approval to Grifol's Application, the Commission has relied upon the information submitted ribyls S.A., and the Commission has asserted that information to be accurate and complete.

By direction of the Commission.

Donald S. Clark Secretary

cc: doel/BrosoleDg26 >>BDC -21.78 -1.15 Td